TrialJournal of managed care & specialty pharmacy2021

Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.

Aditi A Kharat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.